pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$NKTRNEKTAR THERAPEUTICS

$NKTR74.53-2.04%
San Francisco, CA, USupdated 10h ago

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
4
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
rezpegaldesleukin
Alopecia Areata

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (2)
Aug 13, 2026
earnings
$NKTR74.53-2.04%
8d ago
NEKTAR THERAPEUTICS earnings
NEKTAR THERAPEUTICS
→
Aug 6, 2026
earnings
$NKTR74.53-2.04%
15d ago
NEKTAR THERAPEUTICS earnings
NEKTAR THERAPEUTICS
→
view all catalysts →

Active trials

  • phase2A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)active not recruitingn=94
  • phase2A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitisactive not recruitingn=396
  • phase2Study of NKTR 255 in Combination With Cetuximab in Solid Tumorscompletedn=25
  • phase3NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphomaterminatedn=15
  • phase2A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)completedn=291
  • phase1A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19completedn=30
  • phase1A Study of LY3471851 in Participants With Psoriasiscompletedn=30
  • phase1A Study of LY3471851 in Participants With Eczemacompletedn=48
more trials →
🐶 Hiring Signal
No open roles indexed yet — view NEKTAR THERAPEUTICS jobs →

News

  • Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
    Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
    biopharma_dive · 9d ago
  • Q32 bounces back to claim study success for alopecia drug
    Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.
    biopharma_dive · 1mo ago
  • Sanofi posts upbeat sales as R&D pressure builds
    A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.
    biopharma_dive · 3mo ago
identifiers
ticker
$NKTR
SEC CIK
0000906709
country
US
source
sec_tickers
top tags
Dermatology1
mentioned in
3news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 39m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?